GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
Q

Q/C Technologies QCLS · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.37

+8.76%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Q/C Technologies

From its filings with the US Securities and Exchange Commission

SEC filings

Q/C Technologies is based in New York, New York and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker QCLS. The SEC classifies its business as in vitro & in vivo diagnostic substances. In the fiscal year to 31 December 2019, it reported revenue of $1.6m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
24 Jul 2008
Employees
9
Website
ir.mymd.com ↗
Head office
1185 AVENUE OF THE AMERICAS, NEW YORK, NY, 10036
Incorporated in
DE
Classification
In Vitro & In Vivo Diagnostic Substances
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Mr. Joshua SilvermanExecutive Chairman of the Board, since 2018$207,000
  • Mr. Ian RhodesInterim Chief Financial Officer$162,000
  • Dr. Mitchell GlassChief Medical Officer, Director, since 2024$182,333
  • Mr. Bruce BernsteinDirector
  • Mr. Christopher SchreiberDirector, since 2017$244,800
  • Mr. Stephen FrisciaIndependent Director$38,300
  • Mr. Bill WhiteIndependent Director$92,000
  • Mr. Robert SchatzInvestor Relations, since 2021

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • MyMD-1 targets multiple autoimmune diseases including multiple sclerosis and rheumatoid arthritis.
  • Supera-CBD is a synthetic CBD analog for treating epilepsy and anxiety disorders.
  • The company focuses on clinical-stage drug development for aging and autoimmune conditions.

Weaknesses

  • The company has only 9 full-time employees in Baltimore, Maryland.
  • MyMD-1 is still in clinical stages without approved treatments.
  • Supera-CBD development is in early stages without market approval.

Opportunities

  • The aging population in the US presents a growing market for autoimmune disease treatments.
  • Pharmaceutical sector growth in Health Care industry supports new drug development.
  • The US market offers opportunities for clinical-stage companies like MyMD.

Threats

  • The US pharmaceutical market is highly competitive with established players.
  • Regulatory approval delays could impact MYMD-1 and Supera-CBD timelines.
  • Clinical trials for autoimmune treatments face high failure rates in development.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.